Navigation Links
3SBio Inc. Announces Unaudited Third Quarter 2012 Results
Date:11/11/2012

SHENYANG, China, Nov. 11, 2012 Third Quarter 2012 Financial Highlights:

  • Total net revenues increased by 22.5% over the third quarter of 2012 to RMB180.6 million (US$28.7million), compared to RMB147.4 million (US$23.1 million) in the third quarter of 2011.
  • Operating income decreased by 5.1% to RMB38.1 million (US$6.1 million), compared to operating income of RMB40.1 million (US$6.3 million) in the third quarter of 2011.
  • GAAP net income attributable to 3SBio Inc. decreased by 34.5% to RMB22.1 million (US$3.5 million), compared to net income of RMB33.7 million (US$5.3 million) in the third quarter of 2011. Non-GAAP net income attributable to 3SBio Inc. decreased by 7.6% to RMB31.2 million (US$5.0 million), compared to net income of RMB33.7 million (US$5.3 million) in the third quarter of 2011.
  • GAAP net income attributable to 3SBio Inc. per American Depositary Share ("ADS") on a fully-diluted basis decreased by 35.3% to RMB0.97 (US$0.15) compared to net income per ADS on a fully-diluted basis of RMB1.50 (US$0.23) for the third quarter of 2011. Non-GAAP net income attributable to 3SBio Inc. per American Depositary Share ("ADS") on a fully-diluted basis decreased by 8.7% to RMB1.37 (US$0.22) compared to net income per ADS on a fully-diluted basis of RMB1.50 (US$0.23) for the third quarter of 2011.
  • Cash, cash equivalents and time deposits were RMB852.6 million (US$135.7 million, including restricted cash of RMB0.7 million) at September 30, 2012.
  • First Nine Months 2012 Financial Highlights:

  • Total net revenues increased by 26.0% over the first nine months of 2012 to RMB506.0 million (US$80.5 million), compared to RMB401.7 million (US$63.0 million) in the first nine months of 2011.
  • Operating income increased by 22.8% to RMB117.3 million (US$18.7 million), compared to operating income of RMB95.6 million (US$15.0 million) in the first nine months of 2011.
  • GAAP net income attributable to 3SBio Inc. decreased by 1.1% to RMB85.2 million (US$13.6 million), compared to net income of RMB86.2 million (US$13.5 million) in the first nine months of 2011. Non-GAAP net income attributable to 3SBio Inc. increased by 22.5% to RMB105.7 million (US$16.8 million), compared to net income of RMB86.2 million (US$13.5 million) in the first nine months of 2011.
  • GAAP net income attributable to 3SBio Inc. per ADS on a fully-diluted basis decreased by 1.8% to RMB3.76 (US$0.60) compared to net income per ADS on a fully-diluted basis of RMB3.83 (US$0.60) for the first nine months of 2011.  Non-GAAP net income attributable to 3SBio Inc. per ADS on a fully-diluted basis increased by 21.5% to RMB4.65 (US$0.74) compared to net income per ADS on a fully-diluted basis of RMB3.83 (US$0.60) for the first nine months of 2011.
  • Third Quarter 2012 Business Highlights Operations

  • EPIAO, the Company's flagship injectable recombinant human erythropoietin (EPO) product, demonstrated strong growth with net revenue in the third quarter of 2012 rising 16.2% to RMB100.6 million (US$16.0 million), compared to RMB86.6 million (US$13.6 million) in the third quarter of 2011.
  • Net revenues for TPIAO, the Company's novel recombinant human thrombopoietin (TPO) product, increased by 24.2% to RMB 57.2 million (US$9.1 million) in the third quarter of 2012, compared to RMB46.0 million (US$7.2 million) in the third quarter of 2011.
  • Net revenues for Iron Sucrose Supplement increased by 27.8% to RMB9.1 million (US$1.4 million) in the third quarter of 2012, compared to RMB7.1 million (US$1.1 million) in the third quarter of 2011.
  • Net export revenues increased by 92.5% to RMB10.3 million (US$1.6 million), accounting for 5.7% of total net revenue in the third quarter of 2012, compared to RMB5.3 million (US$0.8 million), or 3.6% of net revenues in the third quarter of 2011. 
  • Dr. Jing Lou, chief executive officer of 3SBio, commented: 

    "We remain optimistic about the long-term market potential for our core products, EPIAO and TPIAO, however, in the short term, the NDRC's cuts to retail drug price ceilings will put pressure on tender prices. The recently-completed military hospital tender resulted in price cuts in excess of 20% for both EPIAO and TPIAO but the impact on upcoming provincial tenders remains uncertain.  EPIAO and TPIAO volume growth remains strong as access to dialysis treatment in China continues to improve. Due to the growing demand for dialysis services, we recently started construction of a facility in Benxi, Liaoning Province, to manufacture dialysis-related consumables. The new facility is expected to commence operations in 2015/16. We will continue to look for opportunities to broaden our product lines to serve the needs of CKD patients."

    Three Months Ended September 30, 2012 Unaudited Financial Results Net revenues. Net revenues increased by 22.5% to RMB180.6 million (US$28.7 million) for the third quarter of 2012 from RMB147.4 million (US$23.1 million) for the same period in 2011. This increase was largely due to continued strong sales of EPIAO and TPIAO which grew by 16.2% and 24.2%, respectively, over the same period in 2011. TPIAO remained 3SBio's second largest revenue contributor in the quarter, accounting for 31.7% of total net revenues. Export sales increased by 92.5% year-on-year to RMB10.3 million (US$1.6 million), and revenues from Iron Sucrose rose by 27.8% year-on-year to RMB9.1 million (US$1.4 million).

    Gross profit. As a result of continued sales growth from key products, gross profit for the third quarter of 2012 increased by 20.6% to RMB161.8 million (US$25.7 million) from RMB134.1 million (US$21.0 million) for the same period in 2011. Gross margins decreased 1.4% to 89.6% for the third quarter of 2012 from 91.0% for the same period in 2011. The decrease in gross margin was partly attributable to pricing pressure related to the National Development and Reform Commission's cuts to drug ceiling prices.

    Operating expenses. Operating expenses were RMB123.8 million (US$19.7 million) for the third quarter of 2012, representing an increase of 31.6% from RMB94.0 million (US$14.7 million) for the same period in 2011.

  • Research and development ("R&D") costs.  R&D costs for the third quarter of 2012 were RMB21.1 million (US$3.4 million), or 11.7% of net revenues, compared to RMB10.6 million (US$1.7 million), or 7.2% of net revenues, for the same period in 2011. The increase in R&D expenses is primarily attributable to NuPIAO, our second generation version of EPIAO and an anti-TNF compound that targets rheumatoid arthritis, psoriasis and other inflammatory disorders.
  • Sales, marketing and distribution expenses.  Sales, marketing and distribution expenses for the third quarter of 2012 were RMB83.9 million (US$13.3 million), or 46.5% of net revenues, compared to RMB68.2 million (US$10.7 million), or 46.3% of net revenues, for the same period in 2011.
  • General and administrative expenses. General and administrative expenses for the third quarter of 2012 were RMB18.8 million (US$3.0 million), or 10.4% of net revenues, compared to RMB15.5 million (US$2.4 million), or 10.5% of net revenues for the same period in 2011.
  • Operating income. Operating income was RMB38.1 million (US$6.1 million) for the third quarter of 2012, a 5.1% decrease from operating income of RMB40.1 million (US$6.3 million) for the same period in 2011. GAAP operating margin for the third quarter of 2012 was 21.1%, a 6.1% point decrease from operating margin of 27.2% for the same period in 2011. The decrease in operating margin is primarily due to lower gross margins and higher R&D expenses.

    Interest income. Net interest income was RMB5.8 million (US$0.9 million) for the third quarter of 2012, compared to RMB5.0 million (US$0.8 million) for the same period in 2011. The increase in interest income is primarily due to the combined effect of increased time deposits and higher interest rates on time deposits.

    Net income attributable to 3SBio Inc. GAAP net income attributable to 3SBio Inc. was RMB22.1 million (US$3.5 million) for the third quarter of 2012, a 34.5% decrease over net income of RMB33.7 million (US$5.3 million) for the same period in 2011. Net income attributable to 3SBio Inc. per ADS on a fully-diluted basis for the third quarter of 2012 decreased to RMB0.97 (US$0.15) compared to RMB1.50 (US$0.23) for the same period in 2011. Net margin for the third quarter of 2012 was 12.1%, a 10.8% point decrease over net margin of 22.9% for the same period in 2011. 

    Non-GAAP net income attributable to 3SBio Inc. was RMB31.2 million (US$5.0 million) for the third quarter of 2012, a 7.6% decrease over net income of RMB33.7 million (US$5.3 million) for the same period in 2011. Non-GAAP net income attributable to 3SBio Inc. per ADS on a fully-diluted basis for the third quarter of 2012 decreased to RMB1.37 (US$0.22) compared to RMB1.50 (US$0.23) for the same period in 2011. Net margin for the third quarter of 2012 was 17.3%, a 5.6% point decrease over net margin of 22.9% for the same period in 2011.

    The difference between GAAP and non-GAAP net income is due a writedown in the third quarter of RMB 9.1 million (US$1.45 million) in available-for-sale securities, following a decline deemed to be other than temporary in the market value of 3SBio's US$4.5 million investment in the common shares of Isotechnika (TSX:ISA). The carrying value of the investment in Isotechnika as of September 30, 2012 was RMB7.9 million (US$1.3 million).

    Nine Months Ended September 30, 2012 Unaudited Financial Results Net revenues. Net revenues increased by 26.0% to RMB506.0 million (US$80.5 million) for the first nine months of 2012 from RMB401.7 million (US$63.0 million) for the same period in 2011. This increase was largely due to continued strong sales of EPIAO and TPIAO which grew by 20.9% and 26.6%, respectively, over the same period in 2011. TPIAO remained 3SBio's second largest revenue contributor in the first nine months, accounting for an all-time high of 31.5% of total net revenues. Export sales increased by 86.4% year-on-year to RMB26.3 million (US$4.2 million), and revenues from Iron Sucrose rose 42.1% year-on-year to RMB25.8 million (US$4.1 million).

    Gross profit. As a result of continued sales growth from key products, gross profit for the first nine months of 2012 increased by 26.4% to RMB453.3 million (US$72.1 million) from RMB358.5 million (US$56.2 million) for the same period in 2011. Gross margins increased by 0.4% points to 89.6% for the first nine months of 2012 from 89.2% for the same period in 2011. The increase was mainly attributable to improved manufacturing productivity of the new plant.

    Operating expenses. Operating expenses were RMB336.0 million (US$53.5 million) for the first nine months of 2012, representing an increase of 27.8% from RMB263.0 million (US$41.2 million) for the same period in 2011.

  • Research and development ("R&D") costs.  R&D costs for the first nine months of 2012 were RMB54.4 million (US$8.7 million), or 10.8% of net revenues, compared to RMB29.1 million (US$4.6 million), or 7.2% of net revenues, for the same period in 2011. The increase in R&D expenses is primarily attributable to NuPIAO, our second generation version of EPIAO and an anti-TNF compound that targets rheumatoid arthritis, psoriasis and other inflammatory disorders.
  • Sales, marketing and distribution expenses.  Sales, marketing and distribution expenses for the first nine months of 2012 were RMB227.3 million (US$36.2 million), or 44.9% of net revenues, compared to RMB188.9 million (US$29.6 million), or 47.0% of net revenues, for the same period in 2011.  The decrease is mainly attributable to improved sales force productivity following the expansion of the sales force in 2010 and 2011.
  • General and administrative expenses. General and administrative expenses for the first nine months of 2012 were RMB55.0 million (US$8.8 million), or 10.9% of net revenues, compared to RMB46.5 million (US$7.3 million), or 11.6% of net revenues for the same period in 2011.
  • Operating income.  Operating income was RMB117.3 million (US$18.7 million) for the first nine months of 2012, a 22.8% increase from operating income of RMB95.6 million (US$15.0 million) for the same period in 2011. Operating margin for the first nine months of 2012 was 23.1%, a 0.7% point decline from operating margin of 23.8% for the same period in 2011. The decline in operating margin is primarily due to increased R&D expenses. 

    Interest income. Net interest income was RMB18.4 million (US$2.9 million) for the first nine months of 2012, compared to RMB13.8 million (US$2.2 million) for the same period in 2011. The increase is primarily due to the combined effect of increased time deposits and higher interest rates on time deposits.

    Net income attributable to 3SBio Inc. GAAP Net income attributable to 3SBio Inc. was RMB85.2 million (US$13.6 million) for the first nine months of 2012, a 1.1% decrease over net income of RMB86.2 million (US$13.5 million) for the same period in 2011. Net income attributable to 3SBio Inc. per ADS on a fully-diluted basis for the first nine months of 2012 decreased to RMB3.76 (US$0.60) compared to RMB3.83 (US$0.60) for the same period in 2011. Net margin for the first nine months of 2012 was 16.7%, a 4.8% point decrease over net margin of 21.5% for the same period in 2011.

    Non-GAAP net income attributable to 3SBio Inc. was RMB105.7 million (US$16.8 million) for the first nine months of 2012, a 22.5% increase over net income of RMB86.2 million (US$13.5 million) for the same period in 2011. Non-GAAP net income attributable to 3SBio Inc. per ADS on a fully-diluted basis for the first nine months of 2012 increased to RMB4.65 (US$0.74) compared to RMB3.83 (US$0.60) for the same period in 2011. Non-GAAP net margin for the first nine months of 2012 was 20.9%, a 0.6% point decrease over net margin of 21.5% for the same period in 2011. 

    The difference between GAAP and non-GAAP net income is due to writedowns of RMB 11.3 million (US$1.8 million) in the second quarter and RMB 9.1 million (US$1.45 million) in the third quarter in available-for-sale securities, following declines deemed to be other than temporary in the market value of 3SBio's US$4.5 million investment in the common shares of Isotechnika (TSX:ISA). The carrying value of the investment in Isotechnika as of September 30, 2012 was RMB7.9 million (US$1.3 million).

    Conference Call 3SBio's senior management will host a conference call on Monday, November 12, 2012 9:00pm China Standard Time (8:00am US Eastern or 5:00am US Pacific) to discuss its unaudited third quarter 2012 results and recent business activity. The conference call may be accessed using the dial-in numbers below:

    Conference ID: 39479759

    Local dial-in:
    China landline: 800-819-0121
    China mobile: 400-620-8038
    Hong Kong : 852-2475-0994
    United States: 718-354-1231

    International toll-free dial-in:
    Hong Kong:  800930346
    United States:  1-866-519-4004
    United Kingdom:  080-8234-6646

    International toll dial-in: 65 6723 9381

    Replay- Conference ID: 39479759
    A telephone replay will be available two hours after the call until November 20, 2012 at:
    International:  61-2-8235-5000
    United States: 1-866-214-5335

    Webcast
    A live webcast of the conference will be available on the investor relations section of 3SBio's website at www.3sbio.com and at http://www.media-server.com/m/p/z3b7da4s.
    A replay of the webcast will be available within one hour after the conclusion of the call.

    Non-GAAP Financial Measures: Reconciliation of GAAP to Non-GAAP To supplement the Company's financial information presented in accordance with general accepted accounting principles ("GAAP"), the Company has utilized some non-GAAP financial measures to provide investors and management with supplemental measures that facilitate comparisons of operating performance and trends with prior and future operating performance, and that may not otherwise be apparent on a GAAP basis. The non-GAAP financial measure represents non-GAAP net income. The measure may be different from non-GAAP financial measures used by other companies. The presentation of this financial information, which is not prepared under any comprehensive set of accounting rules or principals, is not intended to be considered in isolation or as a substitute for the financial information prepared and presented in accordance with GAAP. Non-GAAP measures have limitations in that they do not reflect all of the amounts associated with the Company's results of operations as determined in accordance with GAAP. These measures should only be used to evaluate the Company's results of operations in conjunction with the corresponding GAAP measures. Please see the attached reconciliation of GAAP to non-GAAP for an explanation of the amounts excluded to arrive at non-GAAP financial measures for the three-month periods ended September 30, 2011 and September 30, 2012 and for the nine-month periods ended September 30, 2011 and September 30, 2012.

    Statement Regarding Unaudited Financial Information The unaudited financial information set forth above is preliminary and subject to adjustments and modifications. The audited financial statements and related notes are to be included in the Company's annual report on Form 20-F for the year ending December 31, 2012. Adjustments and modifications to the financial statements may be identified during the course of the audit work, which could result in significant differences from this preliminary unaudited financial information.

    Currency Convenience Translation For the convenience of readers, certain RMB amounts have been translated into US dollars at the rate of RMB6.2848 to US$1.00, the noon buying rate for US dollars in effect on September 30, 2012 as set forth in the H.10 statistical release of the U.S. Federal Reserve Board.  A rate of 6.3780 was used for comparative purposes as of September 30, 2011, which was the noon buying rate for US dollars on that date for cable transfers of RMB per US dollar as certified for customs purposes by the Federal Reserve Bank of New York.

    About 3SBio Inc.3SBio is a leading, fully integrated, profitable biotechnology company focused on researching, developing, manufacturing and marketing biopharmaceutical products primarily in China.  Its focus is on addressing large markets with significant unmet medical needs in nephrology, oncology, supportive cancer care, inflammation and infectious diseases.  With headquarters and GMP-certified manufacturing facilities in Shenyang, PRC, 3SBio employs over 800 people. Shares trade in the form of American Depositary Shares (ADSs) on the NASDAQ stock market under the ticker symbol "SSRX". Please see www.3SBio.com for more information.

    Cautionary Statement concerning Forward Looking StatementsCertain statements in the disclosures of 3SBio, Inc. (the "Company" or "3SBio") for the third quarter of 2012 ("Disclosures") that are not purely historical in nature may constitute "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995. The Disclosures include the press release, the conference call and any accompanying materials, and any other information issued, released or publicized by the Company with respect to the third quarter and the year of 2012.

    These forward-looking statements address activities, events, conditions, or developments that we currently expect or anticipate to occur in the future, and may include, but may not be limited to, discussions and statements regarding: full year revenue target, business growth and prospects, product pricing trends, the estimated completion of new facilities, government policies and regulations and the impact thereof, market size or patient number or illness prevalence estimates, product development prospects, future pipeline progress, regulatory review, certification and approval prospects, operation plans and objectives, partnerships or collaborations and the outcome thereof, capital expense estimate, future operations and strategies. Forward-looking statements can be identified by such terminology as "believe," "expect," "plans," "strategy," "potential", "prospects," "forecast," "estimate," "project," "anticipate," "aim," "will" or "would", "may" or "might", and words, phrases, expressions, and usages of similar meaning or substance or the negative thereof.

    Forward-looking statements are based on management's current assumptions, beliefs, expectations, and projections, in light of the information currently available, and actual results, performances, or achievements could differ materially from those implied or expressed by the forward-looking statements.  Among the factors that could cause actual results to differ from what the Company currently anticipates may include: regulatory actions such as adverse drug pricing adjustments; government procurement and reimbursement practice; other government policies and regulations;  receipt and timing of regulatory approvals for new facility, products and indications; issues impacting the new facility construction; competition from other domestic and foreign pharmaceutical companies; risks and uncertainties related to cooperation, joint venture, and partnerships; changes in China's healthcare insurance system; the segment market growth for our products; market acceptance of our products; hospital or patient demand for our products; progress of our clinical trials; our ability to enhance production, sales and distribution network and other aspects of operation; our ability to effectively protect intellectual property; changes in the healthcare industry in China; and fluctuations in general economic and business conditions in China.

    For additional information on factors identified above and other risk factors, uncertainties and assumptions, please refer to the Company's filings with the Securities and Exchange Commission at www.sec.gov, and, in particular, "Introduction – Cautionary Statement concerning Forward Looking Statements", Item 3.D "Risk Factors", Item 5. "Operating and Financial Review and Prospects", and other applicable discussions in 3SBio's annual report on Form 20-F for the year ended December 31, 2011.

    All the statements in the Disclosures speak as of the date of the initial release, even if subsequently made available on the 3SBio website or otherwise.  3SBio undertakes no obligation to update or revise these forward-looking statements, whether as a result of new information, subsequent events or otherwise, after the date of this press release.

    Investor Contacts
    Bo Tan
    Chief Financial Officer

    3SBio Inc.
    Tel: + 86 24 2581-1820
    ir@3SBio.com

    Tom Folinsbee
    Director of Investor Relations
    3SBio Inc.
    Tel: + 852 8191-6991
    ir@3SBio.com

     3SBio Inc.
    Unaudited consolidated balance sheets
    (expressed in thousands)
    December 31, 2011September 30, 2012September 30, 2012RMBRMBUS$Assets (unaudited)(unaudited)Current assetsCash and cash equivalents

    245,813354,80856,455Restricted cash

    665667106Time deposits with financial institutions

    499,201467,08574,320Accounts receivable, less allowance for doubtful accounts:December 31, 2011 – RMB2,542; September 30, 2012 – RMB2,190(US$348)

    113,949141,46522,509Notes receivable

    47,24359,6459,490Inventories

    27,60434,2595,451Prepaid expenses and other receivables(including expenses prepaid to related  parties amounting to RMB6,000 and RMB1,250 (US$199 as of December 31, 2011 and September 30, 2012, respectively)

     

     

    32,672 

     

    38,754 

     

    6,166Available-for-sale securities

    22,8307,8551,250Amounts due from related parties

    -1,160185Deferred tax assets

    2,7501,832291Total current assets

    992,7271,107,530176,223Time deposits with financial institutions

    20,00030,0004,773Available-for-sale securities

    10,84811,3321,803Investment in non-consolidated affiliates

    2,2455,062805Property, plant and equipment, net

    198,053206,25932,819Prepaid  land use rights

    17,44817,0362,711Prepayment and noncurrent deposits

    16,8014,123656Intangible assets, net

    49,61546,8397,453Long term receivables, less allowance for doubtful accounts:December 31, 2011 – RMB818; September 30, 2012 – RMB818 (US$130)

    3,1112,493397Deferred tax assets

    26227744Total assets

    1,311,1101,430,951227,684Liabilities and shareholders' equityCurrent liabilitiesAccounts payable

    6,2183,641579Deferred grant income

    37437460Accrued expenses and other payables

    48,38961,5199,789Income tax payable

    8,8942,094333Total current liabilities

    63,87567,62810,761Deferred grant income

    2,02910,4201,658Total liabilities

    65,90478,04812,419Shareholders' equityShare capital - ordinary shares US$0.0001 par value, 500,000,000 shares

    authorized, 154,473,159 and 154,577,456 issued and outstanding as of

    December 31, 2011 and September 30, 2012, respectively

    12412420Additional paid-in capital

    973,218989,676157,471Accumulated other comprehensive loss

    (126,290)(120,566)(19,185)Retained earnings

    387,317472,56475,192Total shareholders' equity attributable to 3SBio Inc.

    1,234,3691,341,798213,498Non-controlling interest

    10,83711,1051,767Total shareholders' equity

    1,245,2061,352,903215,265Total liabilities and shareholders' equity

    1,311,1101,430,951227,684 

    3SBio Inc.
    Unaudited consolidated statements of income
    (expressed in thousands, except per share, per ADS and other share and ADS data)

     For the Three Months EndedFor the Three Months EndedSeptember 30, 2011September 30, 2012RMBUS$RMBUS$(unaudited)(unaudited)(unaudited)(unaudited)Net Revenues:EPIAO

    86,566

    13,573100,620

    16,010TPIAO

    46,002

    7,21357,155

    9,094Intefen

    1,305

    2051,339

    213Inleusin

    563

    88661

    105Iron sucrose

    7,107

    1,1149,080

    1,445Export

    5,339

    83710,277

    1,635Others

    483

    761,427

    227Total net revenues

    147,365

    23,106180,559

    28,729Cost of revenues

    (13,228)

    (2,074)(18,726)

    (2,980)Gross profit

    134,137

    21,032161,833

    25,749Operating expensesResearch and development costs

    (  10,628)

    (1,666)( 21,148)

    (3,365)Sales, marketing and distribution expenses

    (68,217)

    (10,696)(83,888)

    (13,348)General and administrative expenses

    (15,482)

    (2,427)(18,832)

    (2,996)Grant income

    304

    4896

    15Operating income

    40,114

    6,29138,061

    6,055Interest income

    5,024

    7885,849

    931Impairment loss on available-for-sale securities

    -

    -(9,084)

    (1,445)Share of  income/(loss) in  non-consolidated affiliates

    (801)

    (126)355

    56Other losses, net

    (2,122)

    (333)(4,979)

    (792)Total other income/(loss), net

    2,101

    329(7,859)

    (1,250)Income before income tax expense

    42,215

    6,62030,202

    4,805Income tax expense

    (8,448)

    (1,325)(8,035)

    (1,278)Net  income

    33,767

    5,29522,167

    3,527Less: net income attributable to non-controlling interest

    (50)

    (8)(93)

    (15)Net income attributable to 3SBio Inc.

    33,717

    5,28722,074

    3,512Net income attributable to 3SBio Inc. per share:Basic

    0.22

    0.030.14

    0.02Diluted

    0.21

    0.030.14

    0.02Basic weighted average number of shares outstanding

    153,432,948

    153,432,948154,618,237

    154,618,237Diluted weighted average number of shares outstanding

    157,836,261

    157,836,261159,338,465

    159,338,465Net income attributable to 3SBio Inc. per ADS:Basic

    1.54

    0.241.00

    0.16Diluted

    1.50

    0.230.97

    0.15Basic weighted average number of ADSs outstanding

    21,918,993

    21,918,99322,088,320

    22,088,320Diluted weighted average number of ADSs outstanding

    22,548,037

    22,548,03722,762,638

    22,762,638 

     

    3SBio Inc.
    Unaudited consolidated statements of income
    (expressed in thousands, except per share, per ADS and other share and ADS data)

     For the Nine Months EndedFor the Nine Months EndedSeptember30, 2011September 30, 2012RMBUS$RMBUS$(unaudited)(unaudited)(unaudited)(unaudited)Net Revenues:EPIAO

    235,542

    36,930284,847

    45,323TPIAO

    126,033

    19,761159,619

    25,398Intefen

    3,875

    6083,554

    565Inleusin

    1,933

    3031,862

    296Iron sucrose

    18,168

    2,84925,814

    4,107Export

    14,085

    2,20826,256

    4,178Others

    2,096

    3294,046

    643Total net revenues

    401,732

    62,988505,998

    80,510Cost of revenues

    (43,188)

    (6,771)(52,668)

    (8,380)Gross profit

    358,544

    56,217453,330

    72,130Operating expensesResearch and development costs

    (  29,064)

    (4,557)( 54,441)

    (8,662)Sales, marketing and distribution expenses

    (188,891)

    (29,616)(227,254)

    (36,159)General and administrative expenses

    (46,519)

    (7,294)(55,011)

    (8,753)Grant income

    1,491

    234699

    111Operating income

    95,561

    14,984117,323

    18,667Interest income

    13,751

    2,15618,432

    2,933Impairment loss on available-for-sale securities

    -

    -(20,427)

    (3,250)Share of  loss in non-consolidated affiliates

    (781)

    (122)(610)

    (97)Other losses, net

    (557)

    (87)(4,502)

    (716)Total other income/(loss), net

    12,413

    1,947(7,107)

    (1,130)Income before income tax expense

    107,974

    16,931110,216

    17,537Income tax expense

    (21,693)

    (3,401)(24,701)

    (3,930)Net  income

    86,281

    13,53085,515

    13,607Less: net income attributable to non-controlling interest

    (50)

    (8)(268)

    (43)Net income attributable to 3SBio Inc.

    86,231

    13,52285,247

    13,564Net income attributable to 3SBio Inc. per share:Basic

    0.56

    0.090.55

    0.09Diluted

    0.55

    0.090.54

    0.09Basic weighted average number of shares outstanding

    153,053,866

    153,053,866154,568,524

    154,568,524Diluted weighted average number of shares outstanding

    157,583,783

    157,583,783158,913,155

    158,913,155Net income attributable to 3SBio Inc. per ADS:Basic

    3.94

    0.623.86

    0.61Diluted

    3.83

    0.603.76

    0.60Basic weighted average number of ADSs outstanding

    21,864,838

    21,864,83822,081,218

    22,081,218Diluted weighted average number of ADSs outstanding

    22,511,969

    22,511,96922,701,880

    22,701,880 Reconciliations of GAAP net income to non-GAAP net income for the third quarter of 2011 and 2012
    (in RMB thousands, unaudited)
    Three months ended

    September 30, 2011Three months ended

    September 30, 2012GAAP

    Adjustment

    Non-GAAP GAAP

    Adjustment

    Non-GAAP RMB

    US$

    RMB

    RMB

    US$RMB

    US$

    RMB

    RMB

    US$Net income

    33,717

    5,287

    -

    33,717

    5,28722,074

    3,5129,084

    31,158

    4,957The adjustment for the three months ended September 30, 2012 is for the exclusion of the impairment loss of US$1,445,000 (RMB9,084,000) on available-for-sale securities. 

     

    Reconciliations of GAAP net income to non-GAAP net income for the nine months of 2011 and 2012
    (in RMB thousands, unaudited)

     Nine months ended

    September 30, 2011Nine months ended

    September 30, 2012GAAP

    Adjustment

    Non-GAAP GAAP

    Adjustment

    Non-GAAP RMB

    US$

    RMB

    RMB

    US$RMB

    US$

    RMB

    RMB

    US$Net income

    86,231

    13,522

    -

    86,231

    13,52285,247

    13,564

     

    20,427

    105,674

    16,814The adjustment for the nine months ended September 30, 2012 is for the exclusion of the impairment loss of US$3,250,000 (RMB20,427,000) on available-for-sale securities.


    '/>"/>
    SOURCE 3SBio Inc.
    Copyright©2012 PR Newswire.
    All rights reserved


    Related medicine technology :

    1. 3SBio Independent Committee Selects Legal Counsel in connection with Going Private Proposal
    2. 3SBio Inc. Announces Receipt of "Going Private" Proposal at $15 Per ADS
    3. 3SBio Inc. to Hold 2012 Annual General Meeting on October 10, 2012
    4. Apexigen Announces the Filing of an IND by its Partner, 3SBio
    5. 3SBio Inc. Announces Changes to Its Board of Directors
    6. 3SBio Inc. Schedules Unaudited Second Quarter 2012 Results
    7. 3SBio Obtains SFDA Approval to Join Global Phase III Trial for Voclosporin
    8. 3SBio Inc. To Present at the DB Access Asia Conference 2012
    9. 3SBio Inc. Schedules Unaudited First Quarter 2012 Results
    10. Jazz Pharmaceuticals Announces Participation In Three Investor Conferences In November
    11. FDAnews announces Fifth Annual Risk Management & Drug Safety Summit
    Post Your Comments:
    *Name:
    *Comment:
    *Email:
    (Date:5/27/2016)... 27, 2016 Kitov ... focused on late-stage drug development, today announced the ... of pivotal batches required for registration of KIT-302 ... This follows Kitov,s announcement in December ... met its primary efficacy endpoint. "We ...
    (Date:5/27/2016)... YORK , May 27, 2016 ... biotechs, drug manufacturers, health insurance companies all falling under ... small healthcare companies. While not often talked about, these ... The United States is by far ... world. Advanced Medical Isotope Corp. (OTC: ADMD), Nutranomics Inc. ...
    (Date:5/26/2016)... India , May 26, 2016 ... drugs market growth is the emergence of new treatments. ... astaxanthin therapies for osteoarthritis treatment. The therapy is expected ... Moreover, Arthritis Research UK is conducting studies to develop ... arcOGEN study, where the genes involved in osteoarthritis are ...
    Breaking Medicine Technology:
    (Date:5/27/2016)... ... ... Aimed at nurses and employees in the health care world, this installment ... nursing and health care industry. It also provides insight to the developing trends and ... As the nursing industry is coming out of one of the biggest recessions in ...
    (Date:5/27/2016)... ... 27, 2016 , ... With a team of certified experts, ... Aside from its GMP accreditation, Validation Center is also a registered authority of ... and staff. , Validation Center is ISO17025 accredited and only offers its clients ...
    (Date:5/26/2016)... Washington, DC (PRWEB) , ... May 26, 2016 , ... ... the National Hot Dog and Sausage Council (NHDSC) suggests that Americans prefer their dogs ... hot dogs, 63 percent say grilling is their favorite way to cook a hot ...
    (Date:5/26/2016)... California (PRWEB) , ... May 26, 2016 , ... ... associated with discovery of thousands of defective respirators, according to court documents and ... the case of William and Becky Tyler v. American Optical Corporation, Case No. ...
    (Date:5/26/2016)... (PRWEB) , ... May 26, 2016 , ... ... in intellectual property (IP) to its specialty academic programs. , Answering to the ... college’s existing certificate programs in health law, and environmental and land use law. ...
    Breaking Medicine News(10 mins):